Triethylsilane Pharma Grade API, CAS 617-86-7, molecular formula C₆H₁₆Si, and molecular weight 116.28 g/mol, is supplied as a low-viscosity liquid with a density of 0.728 g/mL at 25 °C and a boiling point of 107–108 °C at atmospheric pressure. The product designation “Pharma Grade API” denotes a manufacturer-certified active pharmaceutical ingredient handling pathway for oral and injectable dosage-form development, although compendial monographs do not currently list triethylsilane under Ph. Eur., USP, or JP. Release therefore follows supplier specification and ICH Q3C/Q3D principles rather than a harmonized pharmacopoeial monograph. Two supplier model designations are used: TES-PG-100 for oral solid-dose and granule applications, and TES-PG-200 for parenteral applications. The neat material is flammable, with a closed-cup flash point below 0 °C, and it is insoluble in water but miscible with common non-protic organic solvents. These properties create a defined processing boundary: direct compression of the neat liquid into tablets or granules is not feasible, and solid-state conversion through adsorption, encapsulation, or spray-drying is required before compression.

On pilot-scale solid-dose runs, a recurrent failure mode occurs when the liquid API is blended directly with microcrystalline cellulose in a 600 L high-shear granulator without a prior carrier adsorption step. The low surface tension and low viscosity of triethylsilane cause uneven liquid distribution across the powder bed, yielding granule fragments with Carr index values exceeding 20% and capping during subsequent compression on a rotary press operating at 25 kN precompression force. Fumed silica and colloidal silicon dioxide at 40–60% w/w liquid loading reduce this variability by increasing the wetted surface area and shifting the granulation end-point to a measurable power-consumption plateau on the granulator drive motor. Production-scale data for this specific configuration remain limited to supplier development reports rather than published peer-reviewed studies, but the equipment behavior is consistent with standard liquid-addition granulation dynamics for low-viscosity organosilanes.

Why Does Direct Compression Require Solid-State Conversion for This API?

The neat product cannot be tableted because it remains liquid at ambient temperature and exhibits no plastic deformation or brittle fracture under compaction pressure. To produce a compressible intermediate, the liquid API is adsorbed onto fumed silica, calcium silicate, or porous magnesium aluminometasilicate at controlled addition rates using a 10 L high-shear mixer equipped with a 12 mm rotor-stator head. Adsorption efficiency is measured by solvent-free visual flow and tapped density stability after 24 h of sealed storage at 25 °C and 60% RH. The resulting solid carrier system can be milled through a 0.5 mm screen and blended with sodium starch glycolate and crospovidone for immediate-release tablet formulations. Lubrication with magnesium stearate must be limited to 0.5% w/w because higher levels reduce tablet tensile strength when combined with hydrophobic silane-coated carrier particles.

For capsule filling, the liquid API can be encapsulated directly in hard gelatin or HPMC capsules only if the fill formulation contains a viscosity-building agent such as colloidal silicon dioxide at 5–10% w/w or a semi-solid lipid matrix. Without the viscosity builder, liquid leakage at capsule joints is observed within 72 h at 40 °C/75% RH during accelerated stability screening. HPMC capsules are preferred over gelatin because the lower equilibrium moisture content of HPMC reduces hydrolytic decomposition of the Si–H bond. The capsule fill mass must be checked under USP <755> weight variation limits, and dissolution testing should follow USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl with 0.5% sodium lauryl sulfate. Published dissolution data for triethylsilane capsule formulations are limited; therefore, the surfactant concentration and paddle speed should be justified by product-specific development data rather than compendial precedent.

Residual Solvent Control in Injectable Grade Against ICH Q3C Option 1 Limits

Injectable grade TES-PG-200 is released with stricter residual solvent and elemental impurity limits than oral grade TES-PG-100. Residual solvents are controlled according to USP <467> and Ph. Eur. 2.4.24, with Class 2 solvents below the ICH Q3C Option 1 parenteral limits. The typical manufacturing route for triethylsilane involves reduction of chlorotriethylsilane or hydrosilylation intermediates, which can introduce tetrahydrofuran, methanol, and dichloromethane as process solvents. Headspace GC-FID is used for quantification, and the injectable grade is supplied with a certificate of analysis showing residual solvent concentrations below 600 ppm for methanol, 720 ppm for tetrahydrofuran, and 600 ppm for dichloromethane. These are supplier release criteria, not compendial acceptance thresholds applicable to all triethylsilane sources.

Elemental impurities are controlled under ICH Q3D and USP <232>/<233>. Trace palladium or platinum from catalytic reduction must be below the parenteral permitted daily exposure limits; inductively coupled plasma mass spectrometry is used with a method detection limit below 0.1 ppm for palladium. Bacterial endotoxin testing follows USP <85>, with a release limit of 0.25 EU/mL for the injectable grade. Particulate matter is evaluated by light obscuration per USP <788> after filtration through a 0.2 µm PTFE membrane. The oral grade is not routinely tested for endotoxin or particulate matter because the administration route does not require those controls.

For injectable formulation, triethylsilane is not directly soluble in water and cannot be administered as an aqueous solution without a solubilizing co-solvent or an emulsion carrier. A common development approach uses a premix of 10–20% w/w triethylsilane in polysorbate 80 and soybean oil, followed by high-pressure homogenization at 500–800 bar to form a submicron emulsion. The hydrolytic stability of the Si–H bond must be evaluated at pH 2.0–6.0 and 2–8 °C; above pH 6.0, solvolysis accelerates and releases hydrogen gas, which requires headspace-pressure-rated borosilicate vials and nitrogen purging before terminal sterilization. Terminal sterilization by autoclaving is generally unsuitable because the boiling point of triethylsilane is 107–108 °C and the material may volatilize or react with trace moisture during the sterilization cycle. Sterile filtration through 0.2 µm PTFE or PVDF membranes is the preferred method, but membrane compatibility must be confirmed because low-surface-tension liquids can penetrate hydrophobic membranes if the pressure differential exceeds the membrane bubble point.

When Triethylsilane Replaces Sodium Borohydride in Reductive Amination Workflows

Triethylsilane differs from sodium borohydride and other hydride reagents in byproduct profile, handling safety, and selectivity. Sodium borohydride generates borate salts that must be removed by aqueous workup, whereas triethylsilane generates triethylsilanol and siloxane byproducts that are often more easily separated by distillation or extraction. The Si–H bond in triethylsilane is less reactive than NaBH₄ toward carbonyl groups at neutral pH, but it is effective in reductive amination and in transition-metal-catalyzed hydride transfer. In a typical reductive amination, triethylsilane is used with a catalytic amount of trifluoroacetic acid or a Lewis acid at 0–25 °C, and the reaction is monitored by GC-FID until starting ketone content is below 1.0%. The lower water reactivity of triethylsilane relative to sodium borohydride reduces hydrogen evolution during workup and simplifies scaling in glass-lined reactors.

The difference in boiling point and flash point directly affects process safety. Triethylsilane has a closed-cup flash point below 0 °C, so transfer lines and receiving drums must be electrically grounded and inerted with nitrogen. Trichlorosilane is more hazardous because it hydrolyzes rapidly to hydrogen chloride and requires glass-lined or alloy C-276 equipment rated for acidic service. Triisopropylsilane offers a lower flammability risk due to its higher boiling point, but its steric bulk can slow reaction kinetics in hindered ketone reductions. In pharmaceutical manufacturing, the selection between triethylsilane and alternative silanes often hinges on residual solvent removal; triethylsilane is easier to evaporate after workup because its boiling point is 107–108 °C, while triisopropylsilane may require prolonged vacuum distillation at 40–50 °C to reach acceptable residual levels.

For granule and tablet formulations, the liquid state of triethylsilane creates a difference from solid-state API powders that can be directly blended and compressed. Solid APIs with a mean particle size below 100 µm often require only dry granulation or roller compaction for tabletability. Triethylsilane, by contrast, must be converted into a non-liquid intermediate before blending, which increases the number of unit operations and creates additional controls for residual solvent, water content, and oxidative degradation. The adsorption process onto fumed silica at 50% w/w loading can increase bulk volume by approximately 2-fold compared with the neat liquid, and the resulting intermediate may have a tapped density below 0.40 g/mL. These low tapped densities require force feeder speeds below 30 rpm during tablet compression to prevent die-filling variability and weight variation outside USP <905> limits. If the liquid is absorbed on magnesium aluminometasilicate instead of fumed silica, the tapped density can be increased to 0.50–0.60 g/mL, but the higher carrier alkalinity may accelerate Si–H solvolysis in the presence of moisture.

Storage of bulk triethylsilane Pharma Grade requires sealed stainless steel or glass-lined vessels under a nitrogen blanket. The product should be protected from moisture, acids, bases, and transition-metal salts because these agents catalyze Si–H bond cleavage. Storage at 2–8 °C reduces the formation of high-boiling siloxane impurities, but the material must be warmed to 20–25 °C before transfer to avoid viscosity changes and condensation. For injectable grade, the container closure system is typically a borosilicate glass vial with a PTFE-lined septum, prescored under nitrogen, and the fill volume should not exceed 80% of the vial capacity to allow for potential hydrogen evolution during short-term temperature excursions.